Frontier Capital Management
PVLA icon

Frontier Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Frontier Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$73.2M Buy
478,833
+104,798
+28% +$12.7M 0.68% 33
2026
Q1 		$46.6M Buy
+374,035
New +$39M 0.48% 65

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Frazier Life Sciences Management
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Frontier Capital Management's PVLA Position: Q2 2026 in Review

Frontier Capital Management increased its Palvella Therapeutics (PVLA) stake by 28% in Q2 2026, buying an estimated $12.7M and bringing the position to 478,833 shares worth $73.2M. The position accounts for 0.68% of the portfolio, ranked #33.

Frontier Capital Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Frontier Capital Management held 478,833 shares of Palvella Therapeutics worth $73.2M as of Q2 2026.
  • Frontier Capital Management bought 104,798 Palvella Therapeutics shares in Q2 2026, an estimated $12.7M.
  • Palvella Therapeutics made up 0.68% of Frontier Capital Management's portfolio in Q2 2026, its #33 holding.
  • Frontier Capital Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Frontier Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.